Sentry Investment Management LLC Continues to Hold Stake in Zoetis Inc. (ZTS)
Sentry Investment Management LLC held its position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 38,662 shares of the company’s stock at the close of the second quarter. Sentry Investment Management LLC’s holdings in Zoetis were worth $2,412,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. BlackRock Inc. grew its position in Zoetis by 2,471.1% during the 1st quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock worth $1,925,722,000 after purchasing an additional 34,679,064 shares in the last quarter. Morgan Stanley grew its position in Zoetis by 182.5% during the 1st quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock worth $780,119,000 after purchasing an additional 9,442,207 shares in the last quarter. Janus Henderson Group PLC grew its position in Zoetis by 7,717.4% during the 2nd quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock worth $362,372,000 after purchasing an additional 5,734,776 shares in the last quarter. Marshall Wace North America L.P. purchased a new position in Zoetis during the 1st quarter worth approximately $243,854,000. Finally, Alliancebernstein L.P. grew its position in Zoetis by 55.4% during the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after purchasing an additional 3,695,449 shares in the last quarter. Hedge funds and other institutional investors own 93.19% of the company’s stock.
Zoetis Inc. (ZTS) traded up 0.449% during trading on Tuesday, hitting $66.005. 498,784 shares of the stock traded hands. Zoetis Inc. has a one year low of $46.86 and a one year high of $66.11. The company’s 50 day moving average is $63.94 and its 200 day moving average is $60.97. The company has a market capitalization of $32.28 billion, a P/E ratio of 37.312 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the firm earned $0.49 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. On average, equities analysts forecast that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be given a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.64%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio is 23.73%.
Several research firms have weighed in on ZTS. BidaskClub upgraded shares of Zoetis from a “sell” rating to a “hold” rating in a research report on Friday. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Thursday, October 12th. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research report on Tuesday, September 26th. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research report on Friday, September 1st. Finally, Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, August 25th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the stock. Zoetis presently has an average rating of “Buy” and an average target price of $65.76.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.